Register for IndieBio New York’s Investor Showcase – March 11, 2026

Learn more about investing in HyIvy Health

Our team will get back to you soon to follow up on your inquiry.
Opt-In Checkbox
We don’t spam. Our Privacy Policy and Cookie Policy apply. The site is protected by reCAPTCHA.
HyIvy Health
Reclaiming Pelvic Health
Founded
2020
Employees*
2-10
Funding to Date*
$3,300,000
Website
hyivy.com
* Data source: Crunchbase
Rachel Bartholomew, Founder & CEO
Our device is the treatment I wish I had as a former cancer patient. Because until now the best medicine has to offer is this (holds up the glass tube). And considering 1 in 6 women, and 1 in 10 men, will deal with pelvic pain in their lifetime, that's just not ok.
Waitlist of 300+ clinics for pelvic pain, which hasn’t changed its standard of care in 80+ years.

HyIvy is a medtech company that has already submitted an FDA 510(k) clearance, and has over 300 hospitals, GYNs, and PT clinics on their waitlist. 150 patients have benefitted from the therapy to-date, and this round will get HyIvy into hundreds more at clinics across the San Francisco area

Every gynecologist will tell you that multiple times a day they see patients whose previous condition has left them with chronic pelvic floor disorder and pain. These women may be cancer survivors, suffering through endometriosis, have unexplained vaginismus, recovering from childbirth, or managing menopause. Most of these patients aren’t even treated, instead put through a battery of tests or go on long waitlists for pelvic floor PT.

Built out of the CEO’s own experience, the Floora device empowers patients to rehabilitate from pelvic pain at home. It simultaneously collects novel biomarker data to show objective efficacy, and allows clinicians to monitor and tweak treatment remotely. It’s reimbursed under established Remote Therapeutic Monitoring codes, providing continuous revenue to both clinics and HyIvy.